v-H-ras effector mutants have been assessed for transforming activity and for the ability of the encoded proteins to interact with Raf-1-, B-Raf-, byr2-, ralGDS-, and CDC25-encoded proteins in the yeast two-hybrid system. Transformation was assessed in rat2 cells as well as in a mutant cell line, rv68BUR, that affords a more sensitive transformation assay. Selected mutant Ras proteins were also examined for their ability to interact with an amino-terminal fragment of Raf-1 in vitro. Finally, possible cooperation between different v-H-ras effector mutants and between effector mutants and overexpressed Raf-1 was assessed. Ras transforming activity was shown to correlate best with the ability of the encoded protein to interact with Raf-1. No evidence for cooperation between v-H-ras effector mutants was found. Signaling through the Raf1-MEK-mitogen-activated protein kinase cascade may be the only effector pathway contributing to RAS transformation in these cells.A number of cellular proteins bind Ras and are candidates for downstream effectors that function in cell transformation by the Ras oncogene. The Raf protein kinases (38,54,72,75,76,82), phosphatidylinositol-3-OH kinase (63), P120 GAP (71, 74), neurofibromin (4, 6), ralGDS (35), zeta PKC (18), and a number of other less well-defined species isolated in two hybrid screens (28, 73) all have the property of binding Ras. In each case, the interaction depends on Ras being in the GTPdependent "on" state, and in many cases the interaction has been documented with purified components in vitro. Each interaction also depends on the integrity of the effector region; severely impaired effector mutants generally block the interaction. In contrast, the interaction of Ras with proteins related to the CDC25 class of guanyl nucleotide exchange protein bind Ras in a complex with either GTP or GDP, and this interaction is not generally sensitive to mutations that remodel the effector loop.There is copious evidence that Ras regulation of the Raf family of protein kinases is important for growth and cell transformation. Raf members phosphorylate and activate MEK, a dual-specificity kinase that phosphorylates and activates mitogen-activated protein kinase (MAPK), a serine kinase that has multiple targets (14,15,30,40). Growth factors that activate MAPK do so largely through activation of Ras (64). Both Raf-1 and MEK1 can be transforming (8,13,46). Ras signaling can largely be blocked by dominant negative Raf-1 and MEK1 mutants (13, 39) and by the drug PD098059, a specific inhibitor of MEK (20).Also, there is growing evidence that Ras can function by Raf-independent mechanisms to bring about oncogenic transformation in some situations. Transformation-impaired mutant Ras species with different binding specificity toward putative effectors show strong synergy in transformation assays, suggesting that multiple Ras-regulated pathways contribute to cell transformation (34,78). Different Ras effector mutants were also reported to cooperate to bring about stimulation of DNA synthesis in f...